Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean daflon C[Author] (1 results)?
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C, Craig VJ, Méreau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J, Bornhauser B, Bourquin JP, Proske A, Stork-Fux C, Murakami M, Sellers WR, Hofmann F, Schwaller J, Tiedt R. Dafflon C, et al. Leukemia. 2017 Jun;31(6):1269-1277. doi: 10.1038/leu.2016.327. Epub 2016 Nov 14. Leukemia. 2017. PMID: 27840424
Targeting multiple nodes of MLL complexes to improve leukemia therapy.
Dafflon C, Tiedt R, Schwaller J. Dafflon C, et al. Oncotarget. 2017 Oct 7;8(53):90614-90615. doi: 10.18632/oncotarget.21598. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207581 Free PMC article. No abstract available.
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Dafflon C, Gaulis S, Barys L, Kapur K, Cornacchione V, Schukur L, Bergling S, Traggiai E, Jansky S, Hellmann L, Engstler BS, Kerr G, de Weck A, Ruddy DA, Naumann U, Stauffer F, Gaul C, Lin Y, Billy E, Weiss A, Hofmann F, Ito M, Tiedt R. Dafflon C, et al. Oncotarget. 2020 Mar 17;11(11):956-968. doi: 10.18632/oncotarget.27493. eCollection 2020 Mar 17. Oncotarget. 2020. PMID: 32215184 Free PMC article.
Feedback